Recently the risk of hospitalization with SJS or TEN in patients initiating lamotrigine was estimated. Sales of low-dose lamotrigine for initiation of treatment were used to estimate numbers of new adult and pediatric users of lamotrigine in Germany. Numbers of cases identified by the German Registry of Severe Cutaneous Reactions were used as the numerator. Based on 1 pediatric case and 9 adult cases during 1998-2000, the risk was estimated as 1.5 in 10 000 adults and 2.1 in 10 000 children.
Was this article helpful?